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Summary Tyrphostins are a group of low molecular weight synthetic inhibitors of protein tyrosine kinases
(PTK). The intracellular domains of the receptors for epidermal growth factor (EGF), transforming growth
factor-a (TGF-a), insulin-like growth factor 1 (IGF-1) possess PTK activity. Since EGF, TGF-a and IGF-1
are considered to play an important role in the proliferation ofpancreatic cancer cells, we studied the effects of
tyrphostins on the growth of three human pancreatic cancer cell lines (MiaPaCa-2, Panc-l and CAV). The
tyrphostins AG17, T23 and T47 all inhibited EGF and serum-stimulated DNA synthesis. AG17 was found to
be the most potent of these agents and caused a dose-dependent but reversible inhibition of cell growth.
Furthermore using an immunoblotting procedure we also found AG17 to inhibit EGF-induced tyrosine
phosphorylation in the MiaPaCa-2 cell line. Tyrosine kinase inhibitors may prove to be useful agents for the
treatment of pancreatic cancer.
It has been proposed that in ductal pancreatic cancer cells
the production of certain growth factors, particularly epider-
mal growth factor (EGF), transforming growth factor-a
(TGF-a) and insulin-like growth factor 1 (IGF-1), together
with the overexpression of their receptors, leads to
unregulated cellular proliferation (Korc et al., 1986; Smith et
al., 1987; Chen et al., 1990; Ohmura et al., 1990; Barton et
al., 1991; Lemoine et al., 1992). These growth factors bind to
specific membrane receptors whose intracellular domains pos-
sess intrinsic protein tyrosine kinase (PTK) activity which is
activated after ligand binding and is essential for signal trans-
duction and biological activity. Interference with this path-
way may provide a means of designing effective therapy for
pancreatic cancer.
The tyrphostins are a recently described family of low
molecular weight protein tyrosine kinase inhibitors (Gazit et
al., 1989; Levitzki, 1990). The characteristic active pharmaco-
phore of these compounds is the hydroxy-cis-benzylidene-
malono-nitrile moiety (Gazit et al., 1991). These compounds
have been demonstrated to be competitive inhibitors of EGF,
insulin and platelet derived growth factor (PDGF) receptor
kinases (Lyall et al., 1989; Bryckaert et al., 1992) and the
protein kinases p6Osrc, p2Iobcr-abl, p185bcr-abl, pl40'b' (Anafi et
al., 1992). In addition, tyrphostins have been shown to be
effective blockers of EGF and PDGF-dependent proliferation
in various cells (Yaish et al., 1988; Bilder et al., 1991). Some
of these agents exhibit selectivity and can discriminate
between, for example, the EGF and insulin receptors or the
PDGF and EGF receptors (Yaish et al., 1988; Bryckaert et
al., 1992). More remarkably some tyrphostins can dis-
criminate between the EGF receptor and the closely related
product of the erbB-2/neu oncogene, structures that are 80%
homologous in the kinase domain (Gazit et al., 1991). It is
considered that this selectivity occurs because the tyrphostins
compete for the substrate site of the kinase, rather than the
ATP binding site, and therefore, since different PTKs possess
different substrate sites it is possible to design selective PTK
inhibitors for each PTK (Levitzki, 1990; Levitzki & Gilon,
1991). The tyrphostins have been tested against a number of
serine/threonine kinases and have been found to be inactive
(Gazit et al., 1989; Yaish et al., 1988).
Because of the importance of tyrosine kinases in the
growth factor induced control of pancreatic cancer cell
growth, our aim was to examine the effect of the tyrphostins
T23, T47 and AG17 on the proliferation of three human
ductal pancreatic cancer cell lines. On finding that AG17 was
the most potent inhibitor ofproliferation, we sought evidence
that this effect was indeed mediated via the inhibition of
PTK activity by studying phosphotyrosine levels within the
MiaPaCa-2 cell line using an immunoblotting technique.
Materials and methods
Protein tyrosine kinase inhibitors
Tyrphostin AG17 (RG50872) was a generous gift from Pro-
fessor A. Levitzki (Department of Biological Chemistry, The
Hebrew University of Jerusalem, Israel). Tyrphostins T23
and T47 were purchased from Biomol Research Laboratories.
Stock solutions of the agents were prepared in dimethyl
sulfoxide (DMSO) and diluted to appropriate concentrations
in culture medium prior to the addition to the cells. An
equivalent dilution of DMSO without the inhibitor served as
a control.
Quantification of tumour cellgrowth
MiaPaCa-2 and Panc-l are both poorly differentiated human
ductal pancreatic carcinoma cell lines and were obtained
from the European Cell Culture Collection. CAV was
derived from a moderately differentiated ductal carcinoma
and was kindly provided by Dr D. Beauchamp (Department
of Surgery, University of Texas Medical Branch, Galveston,
USA). MiaPaCa-2 and Panc-1 were routinely maintained as
monolayers in Dulbecco's Modified Eagle's Medium
(DMEM)(ICN/Flow) containing 10% foetal calf serum
(FCS). CAV cells were grown in 50% RPMI/50% DMEM
containing 5% FCS.
For the measurement of DNA synthesis, tumour cells were
harvested by trypsinisation and after washing were plated out
in 96 well plates at 5 x 104cells ml-' (for serum stimulation)
or 1 x 105cells ml' (for EGF stimulation) in serum free
medium (DMEM only) for 24 h. After this period of growth
arrest the medium was supplemented with 10-8 M EGF
(Gibco) or 10% FCS (Globepharm), these concentrations
having been determined as optimal in preliminary
experiments and reported elsewhere (Gillespie et al., 1992).
Varying concentrations of AG17 (ranging from 10-5 M to
10-7 M), tyrphostin T23 or tyrphostin T47 (both ranging
from 10-4 M to 10-6 M) were added to these cultures. The
cells were incubated for 48 h at 37°C. DNA synthesis was
assessed for the final 8 h by adding 0.5 tLCi 3H-thymidine/
well. The cells were then collected onto filter mats using a
semi-automatic harvester (Inotech, Switzerland). Scintillation
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fluid was added to individual filter discs and the cell
associated radioactivity counted in a beta counter (Packard
1900CA Tricarb).
For cell growth experiments the cells were again harvested
by trypsinisation, washed and plated out in 24 well plates at
3 x I04cells ml-' (for serum stimulation) or 8 x I04cells ml-
(for EGF stimulation) in serum-free medium (SFM) for 24 h.
After this period of serum starvation the medium was sup-
plemented with l0-8 M EGF or 10% FCS with or without
tyrphostin AG17. The cells were incubated at 37°C and cell
numbers were determined using a Coulter Counter, at timed
intervals following the initiation of culture.
Immunoblotting
MiaPaCa-2 cells were plated out in six well dishes in DMEM
containing 10% FCS and allowed to grow for 3 days. Prior
to the addition of AG17, the cells were incubated in SFM for
24 h. Following the preincubation with AG17 (24 h) the cells
were stimulated with EGF (10-8 M) for 15min. These cells
were then lysed with sample buffer (0.06 M Tris containing
2% SDS, 100 mM DTT, 10011M sodium orthovanadate, 10%
glycerol, 0.001% bromophenol blue, pH 6.8) and boiled for
5 min. The protein concentration of the cell lysate was deter-
mined using a bicinchoninic acid kit (Pierce, Rockford,
USA). Samples were stored at - 70'C until analysis.
The Pharmacia Phast system was used for the electro-
phoresis of cell lysate samples (10-15% gradient polyac-
rylamide gels) and semi-dry electroblotting onto PVDF
membrane. The membrane was then processed according to
the following schedule: blocking carried out in PBS/0.05%
Tween-20 containing sheep serum (10%), polyethylene glycol
(5%), human IgG (10%) for 1 h, followed by incubation with
anti-phosphotyrosine antibody directly labelled with
horseradish peroxidase, PY-20 (ICN/Flow) (1 jsg ml-') for
1 h and finally washed in 50 mM Tris/0.15 M NaCl/0.05%
Tween-20 (1 x 15 min; 4 x 5 min). The membrane was then
immersed in enhanced chemiluminescent reagent (Amersham)
for 1 min and tyrosine phosphorylated protein bands were
detected by photographic exposure of autoradiographic film
for 30 s to 30min.
Results
Inhibition ofEGFand serum-stimulatedpancreatic cancer cell
DNA synthesis by T23, T47 and AG17
In three separate experiments, DNA synthesis was stimulated
by EGF and FCS in all three of the cell lines. Furthermore,
it can be seen from Table I that the amount of 3H-thymidine
incorporated into these cell lines under the designated control
conditions (serum free medium alone (SFM), SFM plus
10-8 M EGF or SFM plus 10% FCS) at fixed cell densities
was consistent with small standard errors.
The tyrphostins T23 and T47 caused a dose-dependent
inhibition of DNA synthesis in the two poorly differentiated
cell lines MiaPaCa-2 and Panc-1 when cultured with 10-8 M
EGF or 10% FCS (Figures 1 and 2). The moderately differ-
entiated CAV cell line was only made available to us at a
later date but once again it can be seen from Figure 3 that
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Figure 1 Inhibition of EGF-stimulated (a) and serum-stimulated
(b) MiaPaCa-2 M and Panc-lI 0 DNA synthesis by T23, as
measured by 3H-thymidine incorporation. Results are expressed
as a percentage of control (EGF or serum-stimulated cells) and
are the mean ± s.e.m. of three separate experiments in which five
determinations were made. 'P<0.0001 vs control (Student's un-
paired t-test).
AG17 also inhibited the DNA synthesis of all three pan-
creatic cancer cell lines in a dose-dependent manner.
Further scrutiny of the data represented in Figures 1, 2
and 3 demonstrates two additional features in the tyrphostin-
induced inhibition of DNA synthesis in these cell lines. First,
bearing in mind the consistency of the measurement of 'H-
thymidine uptake in the control cultures, on a molar basis
the tyrphostin AG17 appeared to be a consistently more
potent inhibitor of proliferation than did T23 or T47 by a
factor of between 10 and 100-fold. For this reason AG17 was
selected for all subsequent experiments. Second, it can be
seen that the amount of any of the tyrphostins required to
produce an equivalent amount of inhibition of tumour cell
proliferation was greater during culture in 10% FCS than it
was during culture in SFM containing 10-8 M EGF.
Inhibition ofEGFand serum-stimulated pancreatic cancer cell
growth by AG17
The effect of AG17 on EGF and serum-stimulated cell
growth was assessed directly by counting cell number on
days 2, 3 and 6 for EGF-stimulated cells and on days 1, 2
and 3 for serum-stimulated cells since the cells grow more
Table I 3H-thymidine uptake in pancreatic cancer cell lines
FCS SFMA 10-8 EGF SFMb 10% FCS
MiaPaCa-2 (n = 15) 3060 281 112017 432 1247 36 42148 892
Panc-l (n = 15) 1713 231 6621 566 1069 50 -25471 892
CAV (n=15) 2418±59 11119±586 1343 129 16793±713
Data expressed as mean (± s.e.m.) counts per minute. aSerum-free medium-base
line level in EGF experiments. bSerum free medium-base line level in 10% FCS
experiments. Differences in counts per minute between SFMa and SFMb is due to a
greater number of cells being plated out in the EGF experiment (see Materials and
methods).1124 J. GILLESPIE et al.
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Figure 2 Inhibition of EGF-stimulated (a) and serum-
stimulated (b) MiaPaCa-2 * and Panc-I 0 DNA synthesis by
T47, as measured by 3H-thymidine incorporation. Results are
expressed as a percentage of control (EGF or serum-stimulated
cells) and are the mean ± s.e.m. of three separate experiments in
which five determinations were made. 'P<0.000l, P<0.05 vs
control (Student's unpaired t-test).
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Figure 3 Inhibition of EGF-stimulated (a) and serum-
stimulated (b) MiaPaCa-2 _, Panc-l = and CAV S
DNA synthesis by AG17, as measured by 3H-thymidine incor-
poration. Results are expressed as a percentage of control (EGF
or serum-stimulated cells) and are the mean ± s.e.m. of three
separate experiments in which five determinations were made.
*P<0.0001, A P<0.05 vs control (Student's unpaired t-test).
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Figure 4 Inhibition of EGF-stimulated MiaPaCa-2 (a), Panc-I
(b) and Cav (c) cell growth by AG17. Each point is the mean of
triplicate determinations. The standard errors have been omitted
for clarity, but in all cases they were less than 10% of the
mean.
slowly in serum free medium containing EGF only. In all
three cell lines AG17 inhibited pancreatic cancer cell growth
in a time and dose-dependent manner (Figures 4 and 5).
AG17 appeared not to be toxic to any of the pancreatic
cancer cells studied as measured by the ability of the cells to
exclude trpyan blue (all cultures contained >95% viable
cells at termination of culture).
The ability of cells to recover after treatment with AG17
was also investigated. Figure 6 demonstrates that the growth-
inhibitory effect of the tyrphostin on the MiaPaCa-2 cell line
was reversible following replacement of AG17-containing
medium with fresh medium.
Inhibition ofEGF-induced tyrosine phosphorylation by AG17
in the MiaPaCa-2 cell line
It has previously been shown that tyrphostins are potent
inhibitors of tyrosine kinase activity in a variety of non-
pancreatic cells in vitro (Lyall et al., 1989; Bryckaert et al.,
1992; Reddy et al., 1992). To confirm that tyrphostin AG17
can inhibit tyrosine phosphorylation in pancreatic cancer
cells, we examined the effect of AG17 on EGF-stimulated
MiaPaCa-2 cells, which contain relatively high numbers of
EGF receptors (Korc et al., 1986). After a 15 min exposure
of these cells to EGF, immunoblotting analysis using an
anti-phosphotyrosine antibody demonstrated a dramatic in-
crease in tyrosine phosphorylation of multiple proteins.
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Figure 6 Reversibility of the effects of AG17 on pancreatic
cancer cells. MiaPaCa-2 cells were grown in DMEM with 10%
serum and either 10-5 M, 5 x 10-6 M or 2.5 x 10-6 M AG17. Cells
were counted on days 1, 2 and 3. On day 3, medium was changed
and the cells split into groups. Three groups were grown in the
continued presence of AG17 (control cells) and the cells in the
other groups washed and given fresh medium containing no
AG17.
kD
200-
US S 1 2 3 4
Figure 5 Inhibition of serum-stimulated MiaPaCa-2 (a), Panc-I
(b) and Cav (c) cell growth by AG17. Each point is the mean of
triplicate determinations. The standard errors have been omitted
for clarity, but in all cases they were less than 10% of the
mean.
AG17 inhibited this phosphorylation, notably of a 170kD
band which corresponds to the molecular weight of the EGF
receptor (Figure 7). The dose dependent effect of AG17 on
this phosphorylation appeared to be similar with that seen on
proliferation.
Discussion
Several reports have demonstrated that in ductal pancreatic
cancer cells tyrosine kinase activity is elevated and is con-
sidered to be related to the autocrine production of certain
growth factors and the overexpression of their receptors
which possess intrinsic tyrosine kinase activity (Korc et al.,
1986; Smith et al., 1987; Ohmura et al., 1990; Barton et al.,
1991; Lemoine et al., 1992). This knowledge provides an
opportunity to target a specific component of the autocrine
loop in pancreatic cancer cells with a view to therapeutic
manipulation. In this paper, although all three tyrphostins
inhibited pancreatic cancer cell replication, we have shown
that AG17 was the most potent inhibitor of EGF and serum-
stimulated DNA synthesis and growth in pancreatic cancer
cells by a mechanism that appears largely dependent on the
inhibition of protein tyrosine kinases. In keeping with other
published data using different analogues, the effects of these
agents seemed principally cytostatic and reversible when the
drug was removed from the culture medium.
The effect of tyrphostin AG17 (RG50872) on platelet
derived growth factor (PDGF) and EGF-induced DNA syn-
thesis in rabbit vascular smooth muscle cells has been
97.4-
46-
Figure 7 Inhibition of EGF-induced tyrosine phosphorylation in
the MiaPaCa-2 cell line. U = unstimulated cells; S = EGF-
stimulated cells;
I = 10-5 M AG17; 2 = 10-6 M AG17; 3 = 5 x
10-7 M AG17; 4 = 10-7 M AG17.
previously examined and AG17 was found to be more
specific for PDGF than for an equieffective dose of EGF
(IC50 PDGF 0.04 ELM, EGF 0.22lIM) (Bilder et al., 1991). It is
unlikely that our pancreatic cancer cell lines express receptors
for PDGF since Beauchamp et al. (1990) have shown that
PDGF had no effect on the growth of MiaPaCa-2 and
Panc-1 in vitro. However in our pancreatic cancer DNA
synthesis studies we have found AG17 to be 10-100 times
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more potent than the commercially available tyrphostins T23
and T47. It was for this reason that all further work was
conducted using AG17 only.
AG17 is a much less effective inhibitor of serum-induced
DNA synthesis and cell growth compared with EGF-stimu-
lated proliferation (Figures 3-5). This weaker inhibition of
serum-dependent growth was expected since not only is EGF
present in low concentrations in serum but also several other,
mostly unidentified, growth factors in serum possibly
stimulate growth through other tyrosine kinase receptors
and/or other pathways not involving tyrosine kinases.
Since tyrphostin AG17 had such a dramatic effect on
EGF-stimulated pancreatic cancer cell growth we also in-
vestigated the effect of AG17 on tyrosine phosphorylation in
one of the cell lines. As predicted, when cells were pretreated
with AG17 and then stimulated with EGF the phospho-
tyrosine level of multiple proteins was reduced. One parti-
cular protein was markedly affected by AG17 and since the
molecular weight is approximately 170 kD we propose this to
be the EGF receptor. However we are currently re-blotting
our samples with anti-EGF receptor antibody to test this.
Another important observation from the immunoblotting
analysis is that the concentrations of AG17 needed to inhibit
tyrosine phosphorylation were similar to those required for
inhibition of EGF-stimulated DNA synthesis and cell
growth.
Our data show that the tyrosine kinase inhibitor AG17 can
inhibit the growth of pancreatic cancer cells. Recently several
tyrosine kinase inhibitors have been shown to inhibit in vivo
growth, in nude mice, of a human squamous cell carcinoma.
Moreover, the combination of tyrphostins with suboptimal
doses of monoclonal antibodies to the EGF receptor have
been found to potentiate one another in inhibiting the
growth of such tumours (Yoneda et al., 1991). Regarding
toxicity, preliminary data from this group suggest that
tyrphostin-treated animals actually increased their appetite
and weight during the 4 weeks of tyrphostin treatment, sug-
gesting that these agents may not be particularly toxic.
Clearly, however, pharmacokinetic and detailed toxicology
studies are now required. Taking this into account, the pre-
sent data raise the possibility that tyrphostins may prove to
be useful new agents for the treatment of pancreatic cancer
and other tumours in which there is increased tyrosine kinase
activity.
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